 |

Anteo Diagnostics Ltd (formerly Bio-Layer Corporation) has commercial processes (patents pending) that provide both performance and manufacturing benefits to a broad array of clinical applications. We are currently marketing these processes to appropriate third parties. Our initial focus is the clinical diagnostic (pathology) industry, specifically, the in vitro diagnostics (IVD) markets (nano- and micron-sized bead manufacturers and IVD suppliers), Point of Care (PoC) markets (membrane manufacturers and PoC suppliers), as well as both scientific and clinical research markets (bead, membrane and instrument manufacturers).
We have engaged nearly all the major bead manufacturers, membrane manufacturers and most of the IVD/PoC suppliers and they are rigorously testing the process in their own laboratories. Given the extensive requirements to validate new processes for human health care products, these assessments take time. Some of the interested parties are nearing the completion of their testing. It is our expectation that commercial products that utilise our Mix&Go technology will be available in the research market in the first quarter of 2010 and that IVD products will be made available once regulatory requirements have been met.
|


 |
 |
Building PartnershipsAnteo's processes enhance capabilities to rapidly develop research and diagnostics assays. A number of agreements have been entered into that provide further revenues with the potential of royalty revenues from commercially successful products. In this manner, Anteo has been instrumental in turning promising biomarkers into sensitive tests that can be used for clinical validation.
|
|

Broker Coverage from Southern Cross Equities
12/08/2010
Geoff Cumming (CEO) Interviewed
19/07/2010
Geoff Cumming (CEO) Interviewed - Click Link to Li
28/01/2010
|